2018 年 10 月 海思科医药集团股份有限公司 2018 年第三季度报告正文 证券代码：002653 证券简称：海思科 公告编号：2018-087 海思科医药集团股份有限公司 2018 年第三季度报告正文 1 海思科医药集团股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王俊民、主管会计工作负责人段鹏及会计机构负责人(会计主管 人员)贺晓梅声明：保证季度报告中财务报表的真实、准确、完整。 2 海思科医药集团股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 同一控制下企业合并 | | 本报告期末 | | | 上年度末 | | | 本报告期末比上年 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ...

海思科医药集团股份有限公司 2018 年半年度报告全文 海思科医药集团股份有限公司 2018 年半年度报告 2018 年 08 月 1 海思科医药集团股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人王俊民、主管会计工作负责人段鹏及会计机构负责人(会计主管 人员)贺晓梅声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、新产品研发风险及生产销售进度低于预期的市场风险 公司储备的新产品非常多，并且已构建起纵横管理科学、组织架构齐全的 技术开发体系和具有国内外领先水平的新产品技术开发平台，培养出了专业能 力出众的科研团队。公司管理层已就新产品的研发可行性、市场前景和推广计 划进行了充分的可行性论证。但是，由于医药新产品研发存在周期长、投资大、 失败率高的固有风险，生产销售涉及到工程建设、试生产、GMP 认证、药品注 册审核、市场推广等诸多环节，尽管公司在技术、人员、资金、市场等方面 ...

海思科医药集团股份有限公司 2018 年第一季度报告正文 证券代码：002653 证券简称：海思科 公告编号：2018-034 海思科医药集团股份有限公司 2018 年第一季度报告正文 2018 年 4 月 1 海思科医药集团股份有限公司 2018 年第一季度报告正文 第一节 重要提示 2 海思科医药集团股份有限公司 2018 年第一季度报告正文 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王俊民、主管会计工作负责人段鹏及会计机构负责人(会计主管 人员)贺晓梅声明：保证季度报告中财务报表的真实、准确、完整。 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 同一控制下企业合并 | | 本报告期 | 上年同期 | | 本报告期比上年同 | | --- | --- | --- | --- | --- | | | | | | 期增减 | | | | 调整前 | 调整后 | 调 ...

海思科医药集团股份有限公司 2017 年年度报告全文 海思科医药集团股份有限公司 2017 年年度报告 2018 年 04 月 1 海思科医药集团股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人王俊民、主管会计工作负责人段鹏及会计机构负责人(会计主管 人员)贺晓梅声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、新产品研发风险及生产销售进度低于预期的市场风险 公司储备的新产品非常多，并且已构建起纵横管理科学、组织架构齐全的 技术开发体系和具有国内外领先水平的新产品技术开发平台，培养出了专业能 力出众的科研团队。公司管理层已就新产品的研发可行性、市场前景和推广计 划进行了充分的可行性论证。但是，由于医药新产品研发存在周期长、投资大、 失败率高的固有风险，生产销售涉及到工程建设、试生产、GMP 认证、药品注 册审核、市场推广等诸多环节，尽管公司在技术、人员、资金、市场等方面进 行了严谨 ...

Financial Performance - Operating revenue for the reporting period was ¥477,449,026.29, representing a year-on-year increase of 71.89%[8] - Net profit attributable to shareholders was ¥74,821,019.46, a slight increase of 1.13% compared to the same period last year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,004,456.27, a decrease of 79.58% year-on-year[8] - Basic earnings per share for the reporting period was ¥0.0693, down 1.00% from the previous year[8] - The weighted average return on equity was 3.85%, a decrease of 5.35% compared to the previous year[8] - Revenue for the first nine months of 2017 was CNY 1,315,457,682.12, an increase of 39.21% year-over-year, driven by growth in product sales and marketing services[19] - The estimated net profit attributable to shareholders for 2017 is projected to be between 226.36 million and 362.18 million RMB, representing a decrease of 20% to 50% compared to the previous year[29] - The net profit for 2016 attributable to shareholders was 452.72 million RMB[29] - The decline in performance is attributed to increased sales expenses and uncertainties related to government subsidies[29] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,865,584,639.06, an increase of 4.07% compared to the previous year[8] - Cash and cash equivalents as of September 30, 2017, were CNY 725,171,164.95, a decrease of 36.78% from the beginning of the year, primarily due to investments and dividends paid to Haibao Life[16] - Accounts receivable as of September 30, 2017, amounted to CNY 402,441,881.86, an increase of 102% from the beginning of the year, mainly due to changes in the marketing model[16] - Long-term equity investments as of September 30, 2017, reached CNY 301,149,870.47, a significant increase of 376.43% from the beginning of the year, due to new investments in Haibao Life[16] - The company reported a 97.46% increase in estimated liabilities as of September 30, 2017, totaling CNY 367,252,056.99, due to increased marketing expenses[18] Expenses - Operating costs for the same period were CNY 396,156,331.76, an increase of 47.93% year-over-year, attributed to the rise in revenue[19] - Research and development expenses as of September 30, 2017, were CNY 253,036,832.39, an increase of 46.53% from the beginning of the year, reflecting increased capitalization of R&D[17] - Sales expenses for the first nine months of 2017 were CNY 559,009,909.10, an increase of 130% year-over-year, due to heightened marketing efforts[19] Shareholder Information - The total number of shareholders at the end of the reporting period was 17,897[12] - The top three shareholders held a combined 73.50% of the shares, with the largest shareholder holding 36.99%[12] - The company has committed to not engaging in any competitive business activities during the period of control by the major shareholders[26] - The company has made commitments to ensure fair transactions and protect the interests of minority shareholders[26] - The company has promised not to reduce its holdings of company stock for six months starting from September 13, 2017[28] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥120,865,259.55, a decrease of 29.55% compared to the previous year[8] - Cash received from sales of goods and services for the first nine months of 2017 was CNY 1,307,962,446.37, an increase of 35.27% year-over-year, driven by increased sales[20] Regulatory Compliance - There are no reported violations regarding external guarantees during the reporting period[30] - The company has not experienced any non-operating fund occupation by major shareholders or their affiliates[30] - The company is adhering to its commitments regarding the use of funds and financial products as per regulatory guidelines[27] - The company has conducted on-site research and communication activities with institutional investors on July 13 and September 7, 2017[32] - Non-recurring gains and losses totaled ¥100,574,402.32 for the year-to-date[10] - Other non-current assets as of September 30, 2017, were CNY 488,833,957.31, an increase of 115% from the beginning of the year, primarily due to increased investment in financial products[17]

Financial Performance - The company's operating revenue for the first half of 2017 was ¥838,008,655.83, representing a 25.60% increase compared to ¥667,196,535.20 in the same period last year[23]. - The net profit attributable to shareholders decreased by 41.74% to ¥138,453,409.15 from ¥237,645,680.22 year-on-year[23]. - The net cash flow from operating activities fell by 56.25% to ¥74,607,153.76, down from ¥170,524,527.08 in the previous year[23]. - The basic earnings per share decreased by 40.91% to ¥0.13 from ¥0.22 in the same period last year[23]. - The total assets at the end of the reporting period increased by 2.08% to ¥3,791,576,117.28 compared to ¥3,714,349,995.02 at the end of the previous year[23]. - The net assets attributable to shareholders decreased by 15.77% to ¥1,907,504,922.04 from ¥2,264,547,988.07 at the end of the previous year[23]. - The company reported a significant decrease in cash flow from operating activities, down 56.25% to ¥74,607,153.76, attributed to market promotion expenses[52]. - The company achieved a revenue of 838 million yuan, representing a year-on-year growth of 25.60%[43]. - The net profit for the period was 138 million yuan, showing a decline of 41.74% compared to the previous year[43]. - The company reported a total profit of CNY 151,355,879.57, a decrease of 43.7% from CNY 268,887,103.57 year-on-year[163]. Market Position and Product Development - The company holds a leading position in the parenteral nutrition market, with a market share of approximately 8% for its multi-phosphatidylcholine injection, which is the only product of its kind in the domestic market[31]. - The company has a robust pipeline of new products and a well-established technical development platform, but faces inherent risks in new product development, including high failure rates and lengthy timelines[8]. - The company has a total of 30 existing sales varieties, most of which are the first or only generic products in China[31]. - The company received 5 new approvals during the reporting period, including 1 production approval and 4 clinical approvals[36]. - There are currently 78 products in the research and development stage, including 14 innovative drugs, 3 biological drugs, and 61 generic drugs[44]. - The company is expanding into cardiovascular and diabetes treatment areas based on its new drug reserves and R&D progress[31]. - The company has applied for a total of 297 patents, with 57 granted, and filed 24 new patent applications during the reporting period[44]. - The company has a total of 12 subsidiaries, focusing on pharmaceutical research, development, and marketing strategies[80]. Financial Strategy and Investments - The company plans not to distribute cash dividends or issue bonus shares during this reporting period[12]. - The company has not engaged in any securities or derivative investments during the reporting period, indicating a conservative investment strategy[63][64]. - The total amount of committed investment projects is CNY 64,735.13 million, with CNY 41,945.26 million already utilized, representing approximately 64.8% of the total[69]. - The company has invested CNY 16,278.24 million in innovative drug development projects, with CNY 7,074.47 million utilized, accounting for 43.46% of the total[70]. - The company has terminated certain fundraising projects and redirected the remaining funds to supplement working capital[69]. - The company has made strategic decisions to adjust fundraising and investment plans based on project performance and funding availability[73]. Risks and Challenges - The company has a significant risk of its leading products being further replicated by other pharmaceutical companies, which could impact market share and financial performance[5]. - The ongoing trend of drug price reductions in the market may lead to a decline in average profit margins for the industry, affecting the company's profitability[6]. - The company faced challenges due to new pharmaceutical policies, impacting its operational environment and market dynamics[43]. - The company faces risks related to the further imitation of its leading products[82]. - The company has engaged in production cooperation with partners to optimize resource utilization and enhance profitability, while also facing risks of potential breaches of cooperation agreements[85]. Environmental and Social Responsibility - The company strictly adheres to environmental protection laws and regulations, with no major environmental pollution incidents reported in the first half of 2017[122]. - The company has initiated protective planting of endangered medicinal materials in Tibet, with trial planting areas of 500 square meters for Boleng melon, 410 square meters for safflower, and 422 square meters for sandborn acacia[117]. - The company plans to provide skill training opportunities for 10 households in Jilin Village, Zhanang County, to improve their living standards and increase annual income[120]. - The company has trained local farmers in planting techniques and field management skills to enhance their capabilities[117]. Shareholder and Corporate Governance - The total number of shares remained unchanged at 1,080,270,000, with limited sale condition shares decreasing by 30,942,777 to 597,082,288, representing 55.27% of total shares[129]. - The number of shareholders at the end of the reporting period was 16,874, with major shareholders holding significant stakes: Wang Junmin at 36.99%, Fan Xiulian at 20.69%, and Zheng Wei at 15.82%[136]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period[139]. - The company has committed to not reduce its shareholding in the company for six months starting from May 12, 2017[96]. - The company has implemented an employee stock ownership plan, with relevant announcements made on January 14, 2017[102].

Financial Performance - The company's revenue for Q1 2017 was ¥272,950,704.12, representing a 56.89% increase compared to ¥173,980,392.40 in the same period last year[8] - Net profit attributable to shareholders was ¥44,355,963.07, a 5.46% increase from ¥42,059,854.59 year-over-year[8] - The net cash flow from operating activities improved significantly, with a net outflow of -¥20,718,189.06, a 68.03% reduction from -¥64,798,660.89 in the previous year[8] - Revenue for Q1 2017 was CNY 272,950,704.12, representing a year-on-year increase of 56.89, attributed to adjustments in the marketing model[17] - Cash received from sales of goods and services in Q1 2017 was CNY 353,938,627.27, up 64.18% year-on-year, reflecting the positive impact of the marketing model adjustments[18] - The net profit attributable to shareholders for the first half of 2017 is expected to be between CNY 213.88 million and CNY 261.41 million, representing a change of -10.00% to 10.00% compared to CNY 237.65 million in the same period of 2016[25] Assets and Shareholder Information - The total assets at the end of the reporting period were ¥3,743,388,591.16, a 0.78% increase from ¥3,714,349,995.02 at the end of the previous year[8] - The net assets attributable to shareholders increased to ¥2,308,012,693.89, up 1.92% from ¥2,264,547,988.07[8] - The total number of shareholders at the end of the reporting period was 16,542, with the top ten shareholders holding significant stakes[12] - Major shareholders include Wang Junmin with 36.99% and Fan Xiulian with 20.69%, both having pledged a portion of their shares[12] Expenses and Cash Flow - Sales expenses for Q1 2017 reached CNY 125,583,619.48, a significant increase of 565.00%, driven by changes in the company's marketing strategy[17] - Cash paid for purchasing goods and services in Q1 2017 was CNY 219,864,576.15, a rise of 143.96% year-on-year, linked to increased academic promotion expenses[18] - Tax and additional charges for Q1 2017 amounted to CNY 4,004,726.72, an increase of 237.33%, driven by the growth in sales[17] Other Financial Metrics - The basic earnings per share remained stable at ¥0.04, unchanged from the previous year[8] - The weighted average return on equity was 1.94%, slightly down from 2.03% in the same period last year[8] - The company reported non-operating income of ¥23,131,366.23, primarily from government subsidies and investment income[9] Future Outlook and Commitments - The company anticipates continuous growth in main business revenue, although there is uncertainty regarding the increase in sales, management, and financial expenses, which may affect profit growth[25] - The company has committed to not using idle raised funds for temporary liquidity support or for permanent liquidity supplementation within the next 12 months[24] Compliance and Governance - There are no violations of external guarantees during the reporting period[26] - There are no non-operating fund occupations by controlling shareholders or their related parties during the reporting period[27] - The company has not conducted any research, communication, or interview activities during the reporting period[28] Prepayments and Deferred Expenses - Prepayments as of March 31, 2017, amounted to CNY 48,567,060.74, an increase of 103.00% compared to the beginning of the year, mainly due to prepayments for goods and consulting fees[16] - Long-term deferred expenses as of March 31, 2017, were CNY 2,315,218.74, an increase of 1,116.00% compared to the beginning of the year, primarily due to new data maintenance fees[16] - Other payables as of March 31, 2017, totaled CNY 228,955,890.54, an increase of 37.09%, mainly due to an increase in sales deposits[17] Cash Receipts - Other operating cash receipts in Q1 2017 were CNY 33,144,489.72, a dramatic increase of 1,878.00%, primarily due to growth in customer deposits[18] - Cash received from investment recoveries in Q1 2017 was CNY 609,998,553.31, a 410.00% increase year-on-year, resulting from the maturity of investment financial products[18]

Financial Performance - The company's operating revenue for 2016 was ¥1,435,606,586.81, representing an increase of 18.41% compared to ¥1,212,453,343.66 in 2015[22]. - The net profit attributable to shareholders for 2016 was ¥452,723,897.47, a growth of 21.65% from ¥372,157,949.35 in 2015[22]. - The net profit after deducting non-recurring gains and losses was ¥245,661,931.00, which is a decrease of 18.04% compared to ¥299,733,234.35 in 2015[22]. - The basic earnings per share for 2016 was ¥0.42, up 20.00% from ¥0.35 in 2015[22]. - The total assets at the end of 2016 were ¥3,714,349,995.02, an increase of 15.08% from ¥3,227,546,193.04 at the end of 2015[22]. - The net assets attributable to shareholders at the end of 2016 were ¥2,264,547,988.07, reflecting a growth of 5.01% from ¥2,156,604,841.49 at the end of 2015[22]. - The company achieved a revenue of 1.436 billion yuan, representing a year-on-year growth of 18.41%[48]. - Net profit reached 453 million yuan, with a year-on-year increase of 21.65%[48]. - The cash dividend payout ratio for 2016 was 109.76% of the net profit attributable to ordinary shareholders[110]. - The total distributable profit for 2016 was 1,050,104,768.05 CNY, with cash dividends accounting for 100% of the profit distribution[110]. Product Development and R&D - The company has a robust pipeline of new products and a leading technical development platform, but faces inherent risks in new product development, including long cycles and high failure rates[8]. - The company has 14 Class 1 new drugs in development, with the first innovative drug expected to be launched in the U.S. around 2019[33]. - The company has developed a total of 49 varieties since its establishment in 2000, with a first generic launch rate exceeding 35%[36]. - There are currently 67 projects in the research and development stage, including 14 innovative drugs, 3 biological drugs, and 50 generic drugs[41]. - The company is focusing on high-end generic drugs in complex therapeutic areas, including liver disease, cardiovascular, diabetes, and antibiotics[33]. - The company is actively involved in the research and development of new pharmaceutical products and technologies[93]. - The company plans to complete the II phase clinical trial of HSK3486 and initiate the III phase trial within the year[99]. Market Environment and Challenges - The company anticipates continued downward pressure on drug prices due to ongoing reforms in drug pricing and medical insurance, which may lead to a decline in average profit margins in the industry[6]. - The pharmaceutical industry is facing significant challenges, with a slowdown in growth and increased production costs due to regulatory changes[94]. - The overall market environment remains challenging, with 52 new pharmaceutical-related policies introduced in 2016[94]. - The company is focusing on the development of high-end generic drugs, which are experiencing rapid price declines[94]. Partnerships and Collaborations - The company has established partnerships for production with Tian Taishan Pharmaceutical and Meida Kang Pharmaceutical, which could enhance profitability but also introduce risks if partners violate agreements[11]. - The company has secured exclusive sales rights for innovative materials from Regentis Biomaterials Ltd. and Laminate Medical Technologies Ltd. in China for 10 to 15 years[43]. - A partnership with Microbion Corporation has been established to obtain exclusive patent rights for a new antibiotic targeting chronic wound infections in China[44]. - The company signed strategic cooperation agreements with major distributors, enhancing resource sharing and collaboration[49]. Production and Operations - The company has expanded its production scale, with new production lines established in multiple locations to support both self-production and contract manufacturing[36]. - The company’s cooperative production accounts for nearly 70% of its total production, ensuring stable quality and capacity[35]. - The production of listed products reached 36.27 million bottles, an increase of 18.9% compared to the previous year[50]. - The company completed 413 batches of raw material drug production, with a 13.4% increase in output compared to 2015[51]. Cash Flow and Investments - The company reported a net cash flow from operating activities of 426,111,876.39 CNY, a decrease of 3.82% from 443,027,933.01 CNY in 2015[69]. - The cash inflow from financing activities increased by 27.22% to 809,772,797.99 CNY, while cash outflow increased by 32.71% to 985,542,117.66 CNY[69]. - The total investment amount for the reporting period was ¥156,284,422.03, reflecting a significant increase of 51.29% compared to ¥103,299,900.80 in the previous year[73]. - The company has made significant equity investments, including ¥16,301,000 in a new drug research firm, representing a 4.60% stake[74]. Shareholder and Governance - The company has ensured that minority shareholders have the opportunity to express their opinions and that their legal rights are protected[106]. - The company’s cash dividend distribution plan for 2016 was approved by the board on April 25, 2017[112]. - The total number of shareholders increased to 15,944 by the end of the reporting period, up from 15,107[167]. - The company has a total of 705,143,472 shares outstanding, with 628,025,062 shares still under restriction[165]. Corporate Social Responsibility - In 2016, the company donated pharmaceuticals worth 2.1424 million yuan for targeted poverty alleviation efforts[147]. - The company also contributed 1 million yuan in cash to the Tibet Autonomous Region Poverty Alleviation Office in October 2016[147]. - The company plans to initiate protective planting of endangered medicinal herbs in 2017, aiming to provide training for local farmers and create job opportunities for 10 individuals[150]. - The company will also start a Tibetan medicine industry project in 2017, seeking deeper involvement in poverty alleviation efforts[150]. Environmental Initiatives - The company has invested over 7.269 million yuan in wastewater treatment facilities, achieving a wastewater comprehensive utilization rate of over 65%[154]. - The company’s environmental protection facilities operated at a 100% efficiency rate, with major pollutant emissions meeting discharge permit requirements[155]. - The company has made significant investments in pollution control facilities, including a new desulfurization and dust removal system costing 568,000 yuan[154]. - The company has implemented a clean production plan, resulting in improved energy efficiency and reduced emissions[155].

Financial Performance - Net profit attributable to shareholders was ¥73,983,829.90, reflecting a growth of 17.71% year-on-year[8] - Operating revenue for the period was ¥277,767,518.37, up by 6.08% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥53,883,012.20, which increased by 22.21% year-on-year[8] - Basic earnings per share were ¥0.07, representing a 16.67% increase compared to the previous year[8] - The net profit attributable to shareholders for 2016 is expected to increase by 20.00% to 30.00%, ranging from 446.59 million to 483.81 million CNY[26] - The net profit for 2015 was 372.16 million CNY, indicating a stable growth in the company's main business operations[26] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,413,113,050.92, an increase of 5.75% compared to the previous year[8] - The net assets attributable to shareholders decreased by 1.81% to ¥2,117,484,128.38 compared to the previous year[8] - Accounts receivable increased by 455% to ¥182,412,004.72 due to sales growth and policy adjustments[16] - Long-term borrowings rose 511% to ¥230,717,880.00, primarily due to an additional ¥200 million two-year bank loan[18] - Inventory increased by 34.42% to ¥105,889,295.85, attributed to growth in raw material stock at a subsidiary[16] - Fixed assets grew by 29.59% to ¥603,838,018.88, mainly from the completion of a factory at a subsidiary[17] - Other payables increased by 45.33% to ¥250,096,275.02, driven by higher marketing promotion costs[18] Cash Flow - The company reported a net cash flow from operating activities of ¥171,565,632.14, which decreased by 21.94% year-on-year[8] - Cash received from the disposal of fixed assets surged 37.85 times to ¥1,821,998.00 due to increased asset disposals[20] - Investment cash outflows decreased by 80.43% to ¥180,012,575.27, reflecting lower new investments compared to the previous year[20] Shareholder Information - The total number of shareholders at the end of the reporting period was 15,328[12] - The largest shareholder, Wang Junmin, holds 36.99% of the shares, amounting to 399,550,400 shares[12] Other Information - The company reported an asset impairment loss of ¥8,837,892.18, a 28.16-fold increase due to higher bad debt provisions[19] - The company has no violations regarding external guarantees during the reporting period[27] - There are no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[28] - The company did not engage in any research, communication, or interview activities during the reporting period[29]

Financial Performance - The company's operating revenue for the first half of 2016 was CNY 667,196,535.20, representing a 20.62% increase compared to CNY 553,156,634.85 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was CNY 237,645,680.22, an increase of 10.67% from CNY 214,742,322.16 year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 135,042,053.47, a decrease of 24.44% compared to CNY 178,720,272.62 in the previous year[21]. - The net cash flow from operating activities was CNY 170,524,527.08, up 21.91% from CNY 139,876,644.86 in the same period last year[21]. - The total assets at the end of the reporting period were CNY 3,377,465,770.01, reflecting a 4.65% increase from CNY 3,227,546,193.04 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased by 5.30% to CNY 2,042,395,007.12 from CNY 2,156,604,841.49 at the end of the previous year[21]. - The basic earnings per share for the first half of 2016 was CNY 0.22, a 10.00% increase from CNY 0.20 in the same period last year[21]. - The diluted earnings per share also stood at CNY 0.22, reflecting a 10.00% increase compared to CNY 0.20 in the previous year[21]. - The weighted average return on equity increased to 11.32% from 9.86% year-on-year, marking an improvement of 1.46%[21]. Research and Development - The company invested CNY 78.9 million in R&D, which is a slight increase of 0.96% year-on-year[35]. - The company obtained 14 clinical approval documents, including for HSK3486, and completed 3 clinical submissions for new formulations[36]. - The company secured exclusive patent rights for MBN-101, a novel antibiotic for chronic wound infections, in China[30]. - The company plans to continue its focus on international collaborations and innovative drug development[30]. Market and Sales - The company's sales revenue reached CNY 667.2 million, representing a year-on-year growth of 20.6%[31]. - Sales expenses surged by 188.35% to CNY 168.9 million due to increased marketing efforts[35]. - The company achieved a gross margin of 71.16% in the pharmaceutical sector, up by 2.51% from the previous year[38]. - The company expanded its market presence by establishing an OTC division and integrating sales channels[36]. Investments and Fundraising - The total investment amount during the reporting period was ¥8,113,125, a decrease of 27.40% compared to the previous year's investment of ¥11,175,660.80[42]. - The total amount of raised funds was ¥73,704.4 million, with ¥694.68 million invested during the reporting period and a cumulative investment of ¥46,236.07 million[53]. - The cumulative amount of raised funds that have been repurposed reached ¥22,644.5 million, accounting for 30.72% of the total raised funds[53]. - The new product production base project has a total investment commitment of ¥25,751.69 million, with ¥17,138 million invested, achieving 100% of the planned investment[54]. - The multi-phosphatidylcholine raw material drug expansion project has a total investment of ¥3,490.6 million, with full investment completed[54]. - The sodium fusidate raw material drug expansion project has only invested ¥2,638.8 million out of a total commitment of ¥9,100.8 million, indicating a significant shortfall[54]. - The marketing network expansion project has fully utilized its committed investment of ¥5,879 million[54]. Financial Position - The total liabilities increased to CNY 1,335,022,724.98 from CNY 1,070,941,351.55, representing a growth of approximately 24.7%[130]. - The company's total equity remained stable at CNY 2,042,443,045.03, unchanged from the previous period[130]. - The company's cash and cash equivalents decreased to CNY 1,159,113,539.04 from CNY 1,194,198,756.40, a decline of about 2.9%[128]. - The company's non-current assets amounted to CNY 1,888,896,362.64, slightly up from CNY 1,841,404,706.28, indicating a growth of about 2.6%[129]. - The company reported a significant increase in accounts receivable, which rose to CNY 164,305,700.76 from CNY 27,831,130.27, marking a substantial increase of approximately 490%[128]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[7]. - The total number of ordinary shareholders at the end of the reporting period was 15,839[115]. - Wang Junmin holds 36.99% of shares, totaling 399,550 shares, with 299,662 shares under lock-up[115]. - Fan Xiulian holds 20.69% of shares, totaling 223,465 shares, with 167,599 shares under lock-up[115]. - Zheng Wei holds 15.82% of shares, totaling 170,877 shares, with 128,158 shares under lock-up[115]. - Shen Ping holds 5.77% of shares, totaling 62,363,847 shares, with 31,181,924 shares under lock-up[115]. - Total locked-up shares released during the reporting period amounted to 77,118,410 shares[113]. - The total number of locked-up shares at the end of the reporting period was 499,115,412 shares[113]. Corporate Governance - The company has not engaged in any major litigation or arbitration matters during the reporting period[78]. - There were no asset acquisitions or sales during the reporting period[80][81]. - The company has made commitments regarding shareholding, including a lock-up period for major shareholders lasting 36 months from the listing date[99]. - The company has not engaged in any securities investments or derivative investments during the reporting period[44][50]. - The company has not held any financial enterprise equity or conducted any entrusted loan activities during the reporting period[43][51]. Accounting and Compliance - The financial statements are prepared based on the assumption of going concern, with no significant issues affecting the company's ability to continue operations identified[170]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that the financial statements reflect a true and complete picture of its financial status as of June 30, 2016[172]. - The company recognizes minority interests and losses separately in the consolidated financial statements, ensuring accurate representation of net profit attributable to minority shareholders[181]. - The company applies the equity method for investments in joint ventures, recognizing its share of assets, liabilities, and income[185].